Haleon plc (LSE/NYSE:HLN), a global leader in consumer health with a market capitalization of $41 billion and impressive gross profit margins of 62%, disclosed today that two of its key executives acquired shares as part of the company's Share Reward Plan.
According to InvestingPro analysis, the company maintains a GOOD financial health score and operates with moderate debt levels. On January 10, 2025, both General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers (NYSE:ROG) participated in the transaction, which involved the acquisition of Partnership Shares and the awarding of Matching Shares.
According to the filing, each executive received 33 ordinary shares at a price of £3.7738, along with an equivalent number of Matching Shares at no cost, bringing the total volume to 66 shares for each. The transactions took place on the London Stock Exchange (LON:LSEG), where the stock has demonstrated notably low price volatility, trading at a P/E ratio of 28.4 and offering a dividend yield of 1.16%.
The company, known for brands such as Advil, Sensodyne, and Centrum, operates in the sector of perfumes, cosmetics, and other toilet preparations. Haleon's commitment to delivering better everyday health is reinforced through its product offerings in Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS).
This latest development is part of Haleon's ongoing efforts to align the interests of its management with those of its shareholders and to incentivize performance. The Share Reward Plan is a mechanism that allows executives to invest in the company's stock, thereby directly tying their financial interests with the company's success.
The information regarding the shareholding comes from a recent filing with the Securities and Exchange Commission and reflects the company's adherence to market regulations, specifically The UK Market Abuse Regulation, which mandates the disclosure of transactions by Persons Discharging Managerial Responsibilities.
Haleon's commitment to transparency is evident in the detailed reporting of these transactions. The company continues to maintain its position in the market through a combination of trusted science, innovation, and a deep understanding of consumer needs.
For deeper insights into Haleon's financial health and future prospects, investors can access comprehensive Pro Research Reports and additional financial metrics through InvestingPro, which covers over 1,400 top stocks with expert analysis and actionable intelligence.
In other recent news, Haleon plc has experienced several significant developments.
The consumer health company reported impressive earnings and revenue results, including the completion of a £230 million off-market share repurchase from Pfizer Inc. (NYSE:PFE) Haleon also increased its stake in the Chinese joint venture, Tianjin TSKF Pharmaceutical (TADAWUL:2070) Co. Ltd, to 88%, and finalized the divestment of its nicotine replacement therapy business to Dr. Reddy's Laboratories SA, in a deal worth up to £500 million.
Additionally, Haleon announced key changes to its board, with David Denton resigning as a Non-Executive Director and Bláthnaid Bergin stepping in as an independent Non-Executive Director. The company's CFO, Dawn Allen, vested an award of Haleon Ordinary Shares and sold a portion to cover tax obligations, retaining a significant number of shares.
Analysts have also provided their insights on Haleon. Bernstein analysts downgraded Haleon's stock from 'Outperform' to 'Market Perform', citing concerns over Oral Care growth and anticipated competition. However, Morgan Stanley (NYSE:MS) maintained an Overweight rating on Haleon's stock, despite a minor reduction in EPS estimates for FY25/26, while Goldman Sachs (NYSE:GS) downgraded Haleon's stock from "Buy" to "Neutral." Berenberg initiated coverage with a "Buy" rating.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.